Drug Description in Trials / DrugBank / KEGG DRUG
Search results
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 |
|---|---|---|---|---|---|---|
| 1 | ALL patients IN THE study will BE treated with ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
| 2 | Continued ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
| 3 | EU-ocrevus | - | - | - | - | 1件: 13 13 💬
|
| 4 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
| 5 | Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬
| 1件: ITGA4 ITGA4 💬
| 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬
|
| 6 | Observation OF ocrelizumab AS treatment IN rrms patients (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
| 7 | Ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 4件: 11 11, 13, 46, 49 💬
|
| 8 | Ocrelizumab / rhumab 2h7 (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬
|
| 9 | Ocrelizumab 300 MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 10 | Ocrelizumab 300MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 11 | Ocrelizumab 300MG/10 ML (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 12 | Ocrelizumab 300MG/10ML (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 13 | Ocrelizumab 500MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬
|
| 14 | Ocrelizumab 600 MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 15 | Ocrelizumab AT home (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 16 | Ocrelizumab dose 1 (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 17 | Ocrelizumab dose 2 and dose 3 (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 18 | Ocrelizumab IV (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 19 | Ocrelizumab SC (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 20 | Ocrevus | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 21 | Ocrevus 300 MG, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 22 | Ocrevus-EU | - | - | - | - | 1件: 13 13 💬
|
| 23 | Ocrevus-US | - | - | - | - | 1件: 13 13 💬
|
| 24 | Perfusion OF treatment ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
| 25 | Short-course ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
| 26 | US-ocrevus | - | - | - | - | 1件: 13 13 💬
|